[Molsidomine in exertion angina]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Stable angina pectoris remains a significant clinical challenge.
• Beta-blockers are a first-line treatment but may not fully control symptoms in all patients.

Purpose of the Study:

• To evaluate the efficacy of Molsidomine as an anti-angina drug.
• To assess its effects on exercise capacity and ischemic parameters.

Main Methods:

• Stress tests were conducted on 50 patients with stable angina.
• Clinical evaluation involved 33 patients refractory to beta-blockers.
• Molsidomine was administered sublingually and orally at various doses (1-2 mg).
• Hemodynamic parameters and ST-segment depression were measured.

Main Results:

• Sublingual Molsidomine (2 mg) significantly increased work required for ST depression (WST1) by 94% and total work by 52%.
• Maximal ST depression (ST max) was reduced by 45% one hour post-administration.
• A synergistic effect was observed in patients on beta-blockers.
• Oral Molsidomine (2 mg) showed significant improvements at 1 and 3 hours, comparable to isosorbide dinitrate and nifedipine.

Conclusions:

• Molsidomine demonstrates significant anti-ischemic and anti-anginal effects.
• It improves exercise tolerance and reduces myocardial ischemia.
• Molsidomine is a viable therapeutic option for angina management, potentially offering synergistic benefits with beta-blockers.